|
1
|
Berstein LM: Metformin in obesity, cancer
and aging: Addressing controversies. Aging). 4:320–329. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Menendez JA, Oliveras-Ferraros C, Cufi S,
Corominas-Faja B, Joven J, Martin-Castillo B and Vazquez-Martin A:
Metformin is synthetically lethal with glucose withdrawal in cancer
cells. Cell Cycle. 11:2782–2792. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ma J, Guo Y, Chen S, Zhong C, Xue Y, Zhang
Y, Lai X, Wei Y, Yu S, Zhang J and Liu W: Metformin enhances
tamoxifen-mediated tumor growth inhibition in ER-positive breast
carcinoma. BMC Cancer. 14:1722014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Currie CJ, Poole CD and Gale EA: The
influence of glucose-lowering therapies on cancer risk in type 2
diabetes. Diabetologia. 52:1766–1777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: A representative population prospective cohort study
of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bodmer M, Becker C, Meier C, Jick SS and
Meier CR: Use of antidiabetic agents and the risk of pancreatic
cancer: A case-control analysis. Am J Gastroenterol. 107:620–626.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niraula S, Dowling RJ, Ennis M, Chang MC,
Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, et
al: Metformin in early breast cancer: A prospective window of
opportunity neoadjuvant study. Breast Cancer Res Treat.
135:821–830. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cazzaniga M, DeCensi A, Pruneri G, Puntoni
M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD,
Pagani G, Dell'Orto P, et al: The effect of metformin on apoptosis
in a breast cancer presurgical trial. Br J Cancer. 109:2792–2797.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gronich N and Rennert G: Beyond
aspirin-cancer prevention with statins, metformin and
bisphosphonates. Nat Rev Clin Oncol. 10:625–642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zannella VE, Dal Pra A, Muaddi H, McKee
TD, Stapleton S, Sykes J, Glicksman R, Chaib S, Zamiara P,
Milosevic M, et al: Reprogramming metabolism with metformin
improves tumor oxygenation and radiotherapy response. Clin Cancer
Res. 19:6741–6750. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ugurlucan M, Caglar IM, Caglar FN, Ziyade
S, Karatepe O, Yildiz Y, Zencirci E, Ugurlucan FG, Arslan AH,
Korkmaz S, et al: Aspirin: From a historical perspective. Recent
Pat Cardiovasc Drug Discov. 7:71–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Half E, Tang XM, Gwyn K, Sahin A, Wathen K
and Sinicrope FA: Cyclooxygenase-2 expression in human breast
cancers and adjacent ductal carcinoma in situ. Cancer Res.
62:1676–1681. 2002.PubMed/NCBI
|
|
13
|
Williams CS, Mann M and DuBois RN: The
role of cyclooxygenases in inflammation, cancer, and development.
Oncogene. 18:7908–7916. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ulrich CM, Bigler J and Potter JD:
Non-steroidal anti-inflammatory drugs for cancer prevention:
Promise, perils and pharmacogenetics. Nat Rev Cancer. 6:130–140.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fang L, Chang HM, Cheng JC, Leung PC and
Sun YP: TGF-β1 induces COX-2 expression and PGE2 production in
human granulosa cells through smad signaling pathways. J Clin
Endocrinol Metab. 99:E1217–1226. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Adler AI, Shaw EJ, Stokes T and Ruiz F;
Guideline Development Group, : Newer agents for blood glucose
control in type 2 diabetes: Summary of NICE guidance. BMJ.
338:b16682009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nathan DM, Buse JB, Davidson MB,
Ferrannini E, Holman RR, Sherwin R and Zinman B; American
DiabetesAssociation, ; European Association for Study of Diabetes,
: Medical management of hyperglycemia in type 2 diabetes: A
consensus algorithm for the initiation and adjustment of therapy: A
consensus statement of the American diabetes association and the
European association for the study of diabetes. Diabetes Care.
32:193–203. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takahashi RU, Miyazaki H, Takeshita F,
Yamamoto Y, Minoura K, Ono M, Kodaira M, Tamura K, Mori M and
Ochiya T: Loss of microRNA-27b contributes to breast cancer stem
cell generation by activating ENPP1. Nat Commun. 6:73182015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bacci M, Giannoni E, Fearns A, Ribas R,
Gao Q, Taddei ML, Pintus G, Dowsett M, Isacke CM, Martin LA, et al:
miR-155 drives metabolic reprogramming of ER+ breast
cancer cells following long-term estrogen deprivation and predicts
clinical response to aromatase inhibitors. Cancer Res.
76:1615–1626. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cabello P, Pineda B, Tormo E, Lluch A and
Eroles P: The antitumor effect of metformin is mediated by miR-26a
in breast cancer. Int J Mol Sci. 17:E12982016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dontu G, Abdallah WM, Foley JM, Jackson
KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells.
Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Charafe-Jauffret E, Ginestier C, Iovino F,
Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F,
Dutcher J, et al: Breast cancer cell lines contain functional
cancer stem cells with metastatic capacity and a distinct molecular
signature. Cancer Res. 69:1302–1313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oliveras-Ferraros C, Cufi S,
Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B
and Menendez JA: Micro(mi)RNA expression profile of breast cancer
epithelial cells treated with the anti-diabetic drug metformin:
Induction of the tumor suppressor miRNA let-7a and suppression of
the TGFβ-induced oncomiR miRNA-181a. Cell Cycle. 10:1144–1151.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Din FV, Valanciute A, Houde VP, Zibrova D,
Green KA, Sakamoto K, Alessi DR and Dunlop MG: Aspirin inhibits
mTOR signaling, activates AMP-activated protein kinase, and induces
autophagy in colorectal cancer cells. Gastroenterology.
142:1504–1515.e3. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yue W, Zheng X, Lin Y, Yang CS, Xu Q,
Carpizo D, Huang H, DiPaola RS and Tan XL: Metformin combined with
aspirin significantly inhibit pancreatic cancer cell growth in
vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and
Bcl-2. Oncotarget. 6:21208–21224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blobe GC, Schiemann WP and Lodish HF: Role
of transforming growth factor beta in human disease. N Engl J Med.
342:1350–1358. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Govinden R and Bhoola KD: Genealogy,
expression, and cellular function of transforming growth
factor-beta. Pharmacol Ther. 98:257–265. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reddi AH: BMPs: From bone morphogenetic
proteins to body morphogenetic proteins. Cytokine Growth Factor
Rev. 16:249–250. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Joshi A and Cao D: TGF-beta signaling,
tumor microenvironment and tumor progression: The butterfly effect.
Front Biosci. 15:180–194. 2010. View
Article : Google Scholar
|
|
31
|
Maurya VK, Jha RK, Kumar V, Joshi A,
Chadchan S, Mohan JJ and Laloraya M: Transforming growth
factor-beta 1 (TGF-B1) liberation from its latent complex during
embryo implantation and its regulation by estradiol in mouse. Biol
Reprod. 89:842013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dixon A and Maric C: 17beta-Estradiol
attenuates diabetic kidney disease by regulating extracellular
matrix and transforming growth factor-beta protein expression and
signaling. Am J Physiol Renal Physiol. 293:F1678–F1690. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ito I, Hanyu A, Wayama M, Goto N, Katsuno
Y, Kawasaki S, Nakajima Y, Kajiro M, Komatsu Y, Fujimura A, et al:
Estrogen inhibits transforming growth factor beta signaling by
promoting Smad2/3 degradation. J Biol Chem. 285:14747–14755. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li YC, Ding XS, Li HM, Zhang Y and Bao J:
Role of G protein-coupled estrogen receptor 1 in modulating
transforming growth factor-β stimulated mesangial cell
extracellular matrix synthesis and migration. Mol Cell Endocrinol.
391:50–59. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Garijo R, Hernández-Alonso P, Rivas C,
Diallo JS and Sanjuán R: Experimental evolution of an oncolytic
vesicular stomatitis virus with increased selectivity for
p53-deficient cells. PLoS One. 9:e1023652014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yerlikaya A, Okur E, Baykal AT, Acilan C,
Boyaci I and Ulukaya E: A proteomic analysis of p53-independent
induction of apoptosis by bortezomib in 4T1 breast cancer cell
line. J Proteomics. 113:315–325. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saji S, Honma N, Hirose M, Hayashi S and
Kuroi K: Translational cell study exploring the role of estrogen
receptor beta expression as a predictive and/or prognostic factor
in breast cancer patients. J Clin Oncol. 27:e221852009.
|
|
38
|
Wiggins AK, Kharotia S, Mason JK and
Thompson LU: α-Linolenic acid reduces growth of both triple
negative and luminal breast cancer cells in high and low estrogen
environments. Nutr Cancer. 67:1001–1009. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
O'Brien AJ, Villani LA, Broadfield LA,
Houde VP, Galic S, Blandino G, Kemp BE, Tsakiridis T, Muti P and
Steinberg GR: Salicylate activates AMPK and synergizes with
metformin to reduce the survival of prostate and lung cancer cells
ex vivo through inhibition of de novo lipogenesis. Biochem J.
469:177–187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Y, Du C, Zhao M, Li M, Zhang N, Liu
Y, Wang J and Luo F: Treatment of colonic transplantation
tumor-bearing mice with a high-dose aspirin in a short period of
time. Int J Colorectal Dis. 31:1099–1100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang Y, Jiang M, Li Z, Wang J, Du C,
Yanyang L, Yu Y, Wang X, Zhang N, Zhao M, et al: Hypoxia and TGF-β1
lead to endostatin resistance by cooperatively increasing cancer
stem cells in A549 transplantation tumors. Cell Biosci. 5:722015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cuzick J, Otto F, Baron JA, Brown PH, Burn
J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ and
Thun M: Aspirin and non-steroidal anti-inflammatory drugs for
cancer prevention: An international consensus statement. Lancet
Oncol. 10:501–507. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhao YS, Zhu S, Li XW, Wang F, Hu FL, Li
DD, Zhang WC and Li X: Association between NSAIDs use and breast
cancer risk: A systematic review and meta-analysis. Breast Cancer
Res Treat. 117:141–150. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rothwell PM, Fowkes FG, Belch JF, Ogawa H,
Warlow CP and Meade TW: Effect of daily aspirin on long-term risk
of death due to cancer: Analysis of individual patient data from
randomised trials. Lancet. 377:31–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rothwell PM, Wilson M, Price JF, Belch JF,
Meade TW and Mehta Z: Effect of daily aspirin on risk of cancer
metastasis: A study of incident cancers during randomised
controlled trials. Lancet. 379:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chan AT, Arber N, Burn J, Chia WK, Elwood
P, Hull MA, Logan RF, Rothwell PM, Schrör K and Baron JA: Aspirin
in the chemoprevention of colorectal neoplasia: An overview. Cancer
Prev Res. 5:164–178. 2012. View Article : Google Scholar
|
|
47
|
Algra AM and Rothwell PM: Effects of
regular aspirin on long-term cancer incidence and metastasis: A
systematic comparison of evidence from observational studies versus
randomised trials. Lancet Oncol. 13:518–527. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sato A, Sunayama J, Okada M, Watanabe E,
Seino S, Shibuya K, Suzuki K, Narita Y, Shibui S, Kayama T and
Kitanaka C: Glioma-initiating cell elimination by metformin
activation of FOXO3 via AMPK. Stem Cells Transl Med. 1:811–824.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Shank JJ, Yang K, Ghannam J, Cabrera L,
Johnston CJ, Reynolds RK and Buckanovich RJ: Metformin targets
ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol.
127:390–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lengyel E, Litchfield LM, Mitra AK, Nieman
KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee W and Romero
IL: Metformin inhibits ovarian cancer growth and increases
sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol.
212:479.e471–479.e10. 2015. View Article : Google Scholar
|
|
51
|
Cantrell LA, Zhou C, Mendivil A, Malloy
KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of
endometrial cancer cell proliferation-implications for a novel
treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mitsuhashi A, Kiyokawa T, Sato Y and Shozu
M: Effects of metformin on endometrial cancer cell growth in vivo:
A preoperative prospective trial. Cancer. 120:2986–2995. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sivalingam VN, Kitson S, McVey R, Roberts
C, Pemberton P, Gilmour K, Ali S, Renehan AG, Kitchener HC and
Crosbie EJ: Measuring the biological effect of presurgical
metformin treatment in endometrial cancer. Br J Cancer.
114:281–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bowker SL, Lin M, Eurich DT and Johnson
JA: Time-varying risk for breast cancer following initiation of
glucose-lowering therapy in women with type 2 diabetes: Exploring
detection bias. Can J Diabetes. 41:204–210. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Rico M, Baglioni M, Bondarenko M, Laluce
NC, Rozados V, André N, Carré M, Scharovsky OG and Menacho Márquez
M: Metformin and propranolol combination prevents cancer
progression and metastasis in different breast cancer models.
Oncotarget. 8:2874–2889. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gagnon B, Roseman M, Kasymjanova G,
MacDonald N, Kreisman H and Small D: Protective effect of metformin
in lung cancer patients. J Clin Oncol. 27:e220632009.
|
|
57
|
Storozhuk Y, Hopmans SN, Sanli T, Barron
C, Tsiani E, Cutz JC, Pond G, Wright J, Singh G and Tsakiridis T:
Metformin inhibits growth and enhances radiation response of
non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J
Cancer. 108:2021–2032. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Anisimov VN, Egormin PA, Piskunova TS,
Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV,
Karkach AS and Romanyukha AA: Metformin extends life span of
HER-2/neu transgenic mice and in combination with melatonin
inhibits growth of transplantable tumors in vivo. Cell Cycle.
9:188–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bodmer M, Meier C, Krähenbühl S, Jick SS
and Meier CR: Long-term metformin use is associated with decreased
risk of breast cancer. Diabetes Care. 33:1304–1308. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Inman GJ: Switching TGFβ from a tumor
suppressor to a tumor promoter. Curr Opin Genet Dev. 21:93–99.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Meulmeester E and Ten Dijke P: The dynamic
roles of TGF-β in cancer. J Pathol. 223:205–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sheng H, Shao J, Hooton EB, Tsujii M,
DuBois RN and Beauchamp RD: Cyclooxygenase-2 induction and
transforming growth factor beta growth inhibition in rat intestinal
epithelial cells. Cell Growth Differ. 8:463–470. 1997.PubMed/NCBI
|
|
63
|
Sheng H, Shao J, O'Mahony CA, Lamps L,
Albo D, Isakson PC, Berger DH, DuBois RN and Beauchamp RD:
Transformation of intestinal epithelial cells by chronic TGF-beta1
treatment results in downregulation of the type II TGF-beta
receptor and induction of cyclooxygenase-2. Oncogene. 18:855–867.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Crew TE, Elder DJ and Paraskeva C: A
cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory
drug enhances the growth inhibitory effect of butyrate in
colorectal carcinoma cells expressing COX-2 protein: Regulation of
COX-2 by butyrate. Carcinogenesis. 21:69–77. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M,
Shen Q, Zhu Y and Zhang Y: Metformin attenuates cardiac fibrosis by
inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res.
87:504–513. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Fan K, Wu K, Lin L, Ge P, Dai J, He X, Hu
K and Zhang L: Metformin mitigates carbon tetrachloride-induced
TGF-β1/Smad3 signaling and liver fibrosis in mice. Biomed
Pharmacother. 90:421–426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Cheng K and Hao M: Metformin inhibits
TGF-β1-induced epithelial-to-mesenchymal transition via PKM2
relative-mTOR/p70s6k signaling pathway in cervical carcinoma cells.
Int J Mol Sci. 17:E20002016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Leonel C, Borin TF, de Carvalho Ferreira
L, Moschetta MG, Bajgelman MC, Viloria-Petit AM and de Campos
Zuccari DA: Inhibition of epithelial-mesenchymal transition and
metastasis by combined TGFbeta knockdown and metformin treatment in
a canine mammary cancer xenograft model. J Mammary Gland Biol
Neoplasia. 22:27–41. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Marinello PC, da Silva TN, Panis C, Neves
AF, Machado KL, Borges FH, Guarnier FA, Bernardes SS,
de-Freitas-Junior JC, Morgado-Díaz JA, et al: Mechanism of
metformin action in MCF-7 and MDA-MB-231 human breast cancer cells
involves oxidative stress generation, DNA damage, and transforming
growth factor β1 induction. Tumour Biol. 37:5337–5346. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Cortes P, Riser BL, Asano K,
Rodríguez-Barbero A, Narins RG and Yee J: Effects of oral
antihyperglycemic agents on extracellular matrix synthesis by
mesangial cells. Kidney Int. 54:1985–1998. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kuiper GG, Enmark E, Pelto-Huikko M,
Nilsson S and Gustafsson JA: Cloning of a novel receptor expressed
in rat prostate and ovary. Proc Natl Acad Sci USA. 93:pp.
5925–5930. 1996; View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Schmierer B and Hill CS: TGFbeta-SMAD
signal transduction: Molecular specificity and functional
flexibility. Nat Rev Mol Cell Biol. 8:970–982. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Lönn P, Morén A, Raja E, Dahl M and
Moustakas A: Regulating the stability of TGFbeta receptors and
Smads. Cell Res. 19:21–35. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Luo K, Stroschein SL, Wang W, Chen D,
Martens E, Zhou S and Zhou Q: The Ski oncoprotein interacts with
the Smad proteins to repress TGFbeta signaling. Genes Dev.
13:2196–2206. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Nomura T, Khan MM, Kaul SC, Dong HD,
Wadhwa R, Colmenares C, Kohno I and Ishi S: Ski is a component of
the histone deacetylase complex required for transcriptional
repression by Mad and thyroid hormone receptor. Genes Dev.
13:412–423. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Stroschein SL, Wang W, Zhou S, Zhou Q and
Luo K: Negative feedback regulation of TGF-beta signaling by the
SnoN oncoprotein. Science. 286:771–774. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Heery DM, Kalkhoven E, Hoare S and Parker
MG: A signature motif in transcriptional co-activators mediates
binding to nuclear receptors. Nature. 387:733–736. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Torchia J, Rose DW, Inostroza J, Kamei Y,
Westin S, Glass CK and Rosenfeld MG: The transcriptional
co-activator p/CIP binds CBP and mediates nuclear-receptor
function. Nature. 387:677–684. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
79
|
Cheskis BJ, Greger JG, Nagpal S and
Freedman LP: Signaling by estrogens. J Cell Physiol. 213:610–617.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: NCCN guidelines insights breast cancer, Version
1.2016. J Natl Compr Canc Netw. 13:1475–1485. 2015. View Article : Google Scholar : PubMed/NCBI
|
